Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 8/20 | 0.85 |
| ▸ | PAK2 | Q13177 | 5/20 | 0.85 |
| ▸ | PKN1 | Q16512 | 5/20 | 0.85 |
| ▸ | PAK3 | O75914 | 3/20 | 0.85 |
| ▸ | PAK4 | O96013 | 4/20 | 0.64 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.61 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.61 |
| ▸ | WEE1 | P30291 | 1/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | CDK4 | P11802 | 5/20 | 0.48 |
| ▸ | CCND1 | P24385 | 5/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.48 |
| ▸ | CDK2 | P24941 | 4/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.48 |
| ▸ | CCND2 | P30279 | 1/20 | 0.47 |
| ▸ | CCND3 | P30281 | 1/20 | 0.47 |
| ▸ | STK4 | Q13043 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384408 | 0.92 | PAK1 (1.00) | PAK1PAK2PKN1PAK3PAK4 | |
| SCHEMBL13554062 | 0.92 | PAK1 (1.00) | PAK1PAK2PKN1PAK3PAK4 | |
| SCHEMBL14824805 | 0.92 | PAK1 (0.89) | PAK1PAK2PKN1PAK3PAK4 | |
| SCHEMBL14681960 | 0.91 | PAK1 (0.71) | PAK1PAK2PKN1PAK3PAK4 | |
| SCHEMBL14681933 | 0.90 | PAK1 (0.85) | PAK1PAK2PKN1PAK3PAK4 | |
| SCHEMBL14681932 | 0.90 | PAK1 (0.78) | PAK1PAK2PKN1PAK3PAK4 | |
| SCHEMBL14693006 | 0.89 | PAK1 (0.84) | PAK1PAK2PKN1PAK3PAK4 | |
| SCHEMBL14824790 | 0.89 | PAK1 (0.68) | PAK1PAK2PKN1PAK3PAK4 | |
| SCHEMBL14824780 | 0.89 | PAK1 (0.68) | PAK1PAK2PKN1PAK3PAK4 | |
| SCHEMBL14684815 | 0.88 | PAK1 (0.67) | PAK1PAK2PKN1PAK3PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11065251-B2 | PAK1 inhibitors and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200323855-A1 | PAK1 INHIBITORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2020-10-15 | — | — | US | disclosed |
| WO-2017192228-A1 | PAK1 INHIBITORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013086451-A2 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013043232-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065251-B2 | PAK1 inhibitors and uses thereof | PAK1, CDC42, CDC42BPG | PAK1 1/4885PAK2 7/4885PKN1 783/4885 |
| US-20200323855-A1 | PAK1 INHIBITORS AND USES THEREOF | PAK1, CDC42, CDC42BPG | PAK1 1/4885PAK2 7/4885PKN1 783/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PAK1 4/4885PAK2 2/4885PKN1 326/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | PAK1 2/4885PAK2 1/4885PKN1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.